Principal Investigator

Thomas
Lad
Awardee Organization

Hektoen Institute For Medical Research
United States

Fiscal Year
2023
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Stroger Hospital of Cook County (SHCC) MU-NCORP Renewal

John H. Stroger Jr, Hospital of Cook County (SHCC) in Chicago, Illinois is the major tertiary care site for the Cook County Health and Hospital System (CCHHS). The majority of cancer cases are from minority-underserved populations and are predominantly African American. The SHCC MU NCORP plans to continue to strengthen and improve coordinated care and clinical research for its minority population through participation in NCTN programs. Dr. Thomas E. Lad will continue as Principal Investigator (PI). The SHCC MU-NCORP will Continue to foster relationships with current cancer research bases to facilitate broad and improved participation in cancer control, prevention, and care delivery research for breast, lung, prostate, gastrointestinal, brain, hematologic, head and neck, and gynecologic cancers; facilitate transfer of state-of-theare quality oncology care and new technology to minority-underserved populations in their own communities, through participation in NCI-approved clinical trials; focus on prevention, control and survivorship as methods for reducing cancer incidence, morbidity and mortality; encourage multidisciplinary cancer care and integrated research at the local level; participate in cancer care delivery research which accrue to trials relevant to process improvement and implementation activities by coordinating the existing infrastructural features of the Cook County Health & Hospitals System and CountyCare's Managed Care Community Network; continue to be a source of annotated tissue and blood samples for translational research projects such as the Early Onset Malignancy Initiative and the Patient Derived Xenograft project; continue scientific activity at the research base level by chairing an ECOG group-wide cancer control study concerning reproductive issues of female cancer patients that was conceived, designed, and initiated by the SHCC MU NCORP; and increase participation in symptom science research.

Publications

  • Pugh SL, Wyatt G, Wong RK, Sagar SM, Yueh B, Singh AK, Yao M, Nguyen-Tan PF, Yom SS, Cardinale FS, Sultanem K, Hodson DI, Krempl GA, Chavez A, Yeh AM, Bruner DW. Exploratory Factor Analysis of NRG Oncology's University of Washington Quality of Life Questionnaire-RTOG Modification. Journal of pain and symptom management. 2017 Jan;53(1):139-145.e2. Epub 2016 Nov 27. PMID: 27899312
  • Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). The AAPS journal. 2017 Sep;19(5):1411-1423. Epub 2017 Jun 15. PMID: 28620884
  • Wyatt G, Pugh SL, Wong RK, Sagar S, Singh AK, Koyfman SA, Nguyen-Tân PF, Yom SS, Cardinale FS, Sultanem K, Hodson I, Krempl GA, Lukaszczyk B, Yeh AM, Berk L. Xerostomia health-related quality of life: NRG oncology RTOG 0537. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2016 Sep;25(9):2323-33. Epub 2016 Feb 25. PMID: 26914104
  • Sharma MR, Mehrotra S, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Velasco M, Overmoyer B, Rugo HS, Ratain MJ, Gobburu JV. Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). Journal of clinical pharmacology. 2020 Apr;60(4):444-452. Epub 2019 Dec 4. PMID: 31802506
  • Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, Dubey A, Greenberger JS, Raben A, Giguere J, Roof K, Videtic G, Pollock J, Safran H, Crane CH. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. JAMA oncology. 2017 Nov 1;3(11):1520-1528. PMID: 28687830